ATXN3 and neoplasm: Together with our discovery that ATXN3 drives tumor evasion of immunosurveillance through promoting PD-L1 transcription, targeting of this druggable enzyme will achieve both chemo- and immune-therapeutic efficacy in antitumor treatment.